Safety and efficacy of vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in previously untreated advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II KEYVIBE-005 study

---

Toullec C., Seo S., Robinson A. G., Chou H., Salman P., Ghiringhelli F., ...More

ANNALS OF ONCOLOGY, 2024 (SCI-Expanded, Scopus)

• Publication Type: Article / Abstract
• Publication Date: 2024
• Doi Number: 10.1016/j.annonc.2024.08.917
• Journal Name: ANNALS OF ONCOLOGY
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, CAB Abstracts, EMBASE, MEDLINE
• Hacettepe University Affiliated: Yes